XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com. All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be applied across a vast array of indications to create victories for patients most in need.

Jaguar Health (NASDAQ: JAGX) (“Jaguar”) is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Napo Pharmaceuticals, a Jaguar company, focuses on developing and commercializing proprietary human pharmaceuticals from plants harvested responsibly from rainforest areas. Jaguar is the majority shareholder of Napo Therapeutics S.p.A., a corporation established by Jaguar in Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, focuses on developing novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults. For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com. For more information about Magdalena Biosciences, visit magdalenabiosciences.com. To read our full social media policy, please visit https://jaguar.health/social-media-policy

Born on a relief mission, DripDrop is committed to defeating dehydration. When you stick to your mission, we stick to ours. As an oral rehydration solution (ORS), every stick of DripDrop ORS is meticulously formulated for fast absorption, with 1/2 the sugar and 3x the electrolytes of sports drinks. Everything you need, nothing you don't. #StickToYourMission

Polaris Pharmaceuticals, is a biopharmaceutical development and manufacturing organization (CDMO) specializing in biologics derived from microbial systems. We have manufactured clinical material for trials in the United States, Europe, China, Taiwan, Australia, and Korea. Polaris Pharma offers a comprehensive range of process and analytical development and high-quality cGMP pre-clinical and clinical manufacturing services. We offer services for the following: • Process Development • Master and Working Cell Bank Propagation • Pre-Clinical/Clinical Manufacturing • QC Method Development • In Process Testing • Release Testing • Stability Storage and Testing • Availability to provide high purity WFI and PW • Custom Buffer and Media Manufacturing • Contract Filling, Labeling, Inspection • Microbial Based Fermentation Products

NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare, skincare, and wound care products. NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution channels such as Amazon. DERMAdoctor® offers more than 30 OTC dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd. NovaBay Pharmaceuticals, Inc. is publicly traded (NYSE: NBY).

i4COLOR is a value-added premedia services partner to brands and agencies. We elevate brands to achieve their full potential. Since 2010, through innovative premedia solutions, we have been elevating brands to a level not seen anywhere else. We perfect how a brand is seen by acting as an outside in-house team dedicated to the integrity of our clients’ brand and delivering an unmatched customer experience. We work with brands, agencies, and printers to perfect the quality of each deliverable, earning the trust of clients and vendors alike. We achieve this through coordination and collaboration from the design phase to the final deliverable creative. Our clients engage with us early to help identify and solve problems before the brand team has finalized the design. When we finally have the files in-hand, we work collaboratively with our clients and print partners to ensure the file build reproduces exactly as intended.

GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible. The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease. We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.

Neurocentria is a late-stage biotechnology company dedicated to discovering and developing novel treatments for neurodegenerative and neuropsychiatric disorders, including ADHD, depression and Alzheimer’s disease. Since 2005, our team has been innovating breakthrough therapies to address the pathophysiology of these disorders, prevent their progression or even reverse their course, reduce symptoms and improve patients’ performance and quality of life. Currently available treatments for these disorders are acting on classical targets identified decades ago, especially for ADHD and depression, with no new approaches introduced during this time. And, too often, patients endure just as much from the side effects of their medications. Our novel therapy, NRCT-101SR, is a new class of treatment for neurological disorders, developed to act on new molecular targets. In preclinical studies, NRCT-101, the API of NRCT-101SR, increased synapse density and plasticity, improving synaptic function. Importantly, NRCT-101 enhanced cognitive function and improved emotional regulation in young animals, and prevented synaptic loss and alleviated cognitive impairment in aged animals. Similar effects of NRCT-101 were seen in models of neuroinflammation. In early-stage human clinical trials, NRCT-101 was shown to: ➫ Improve mood status in 3-7 days versus the several weeks it takes for most medications ➫ Address ADHD symptoms without imposing side effects ➫ Improve cognition for adults with late-life depression, anxiety, ADHD and Alzheimer’s & Alzheimer’s-like symptoms ➫ Produce no negative side effects The FDA recently approved our drug candidate for a pivotal Phase IIb/III human trial for adults with ADHD, a Phase IIb human trial in Alzheimer’s, and we are working on a phase IIb/III human trial in adults with major depressive disorder. We are fully committed to developing novel brain health therapies that are safe, improve people’s conditions and promote healthy communities.

Innersense Organic Beauty continues to push the boundaries of new product development by utilizing organic chemistry to raise the bar on clean, luxurious formulas with professional performance to care for your hair, health and planet. Dedicated to wellness through uplifting affirmations, self care and hair ceremonies, our mission is to inform, inspire and empower beauty professionals and consumers to make healthy choices with a brand that aligns with their personal values. Clean chemistry, radical transparency and a commitment to the environment are our promises to you. This means no parabens, silicones, sulfates, synthetic fragrances or questionable ingredients. It’s your health. It’s our planet.

High Performance Materials (Specialty Chemicals & Polymers) NuGeneration Technologies, "NuGenTec®"​ Develops and Manufactures Specialty Chemical Products for process manufacturers in the areas of Media Storage, Heads, Wafers, Semiconductors, Photovoltaic Cells (Solar Cells), Precision Optics, Printed Circuit Boards, Metal Working (machining), Metal Forming, Metal/Parts Cleaning, Iron and Zinc Phosphate Conversion Coatings, Food and Food Processing Industries, Bottled Water, Federal, State and local government agencies, and most other manufacturing facilities. In addition to our many proven products, we specialize in working closely with our customers to develop custom products to meet your specific requirements. Improving your process through the use of custom formulated products will limit the need for costly equipment upgrades. Product development, "Private Labeling, Formulation development, and MSDS Authoring are among some of the many extra services we offer.